Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00532571 · ClinicalTrials.gov registry record · Phase 2

Effects of Coenzyme Q10 in PSP and CBD

A Phase 2 study of Progressive Supranuclear Palsy and Neurological Disorders, sponsored by Lahey Clinic.

Completed
Registry status
Phase 2
Development phase
1
Study location

NCT00532571: Completed Phase 2 study of Progressive Supranuclear Palsy and Neurological Disorders, sponsored by Lahey Clinic.

NCT00532571 is a Phase 2 study of Progressive Supranuclear Palsy and Neurological Disorders that has completed, run by Lahey Clinic. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00532571, a Phase 2 study of Progressive Supranuclear Palsy and Neurological Disorders, has completed, sponsored by Lahey Clinic.

COMPLETED
Registry status
Phase 2
Development phase
1
Study location

Study Summary

To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).

Interventions

  • DRUG CoQ10

Study Locations (1)

Massachusetts

  • Lahey Clinic - Burlington

Trial Details

FieldValue
Start Date 2004-01
Est. Completion 2005-09
Phase Phase 2
Lahey Clinic

43 total trials

What the finished NCT00532571 record still lists

NCT00532571 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with Progressive Supranuclear Palsy appearing as the primary indexed condition, and to 1 intervention - of which CoQ10 is the first listed.

NCT00532571 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00532571 about?

NCT00532571 is a clinical study titled "Effects of Coenzyme Q10 in PSP and CBD". To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).

What is the current status of trial NCT00532571?

This trial is currently completed. It is a Phase 2 study. The study started on 2004-01. Estimated completion is 2005-09.

What conditions does trial NCT00532571 study?

This clinical trial studies the following conditions: Progressive Supranuclear Palsy, Neurological Disorders.

What interventions are being tested in trial NCT00532571?

The interventions under investigation include: CoQ10 (DRUG).

Who is sponsoring clinical trial NCT00532571?

This trial is sponsored by Lahey Clinic, which has 43 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00532571 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00532571, the US trial registry maintained by the National Library of Medicine. NCT00532571 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.